Literature DB >> 16282301

Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models.

Leslie S Wilson1, Arthur M Strosberg, Kimberly Barrio.   

Abstract

Chagas disease is a parasitic disease in Latin America. Despite vector control programs that have reduced incidence by 70%, there are at least 12-14 million prevalent cases. We used a Markov model to examine strategies for control and treatment of Chagas disease that compared annual costs, life expectancies, and cost-effectiveness of three vector control and drug treatment strategies. Vector control programs alone and vector control plus drug treatment are dominant over no vector control (i.e., less costly and save more lives), and vector control plus drug is highly cost-effective compared with vector control alone. We demonstrated expected changes in deaths over time resulting from various prevention approaches. Vector control affects primarily incidence, not decreasing deaths and prevalence for 30 years, while drug treatment affects prevalence and deaths immediately. The best strategy to combat Chagas disease is combinations of vector control and a potential new drug.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282301

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

1.  A systems approach to vaccine decision making.

Authors:  Bruce Y Lee; Leslie E Mueller; Carla G Tilchin
Journal:  Vaccine       Date:  2016-12-22       Impact factor: 3.641

2.  Modeling the economic value of a Chagas' disease therapeutic vaccine.

Authors:  Bruce Y Lee; Kristina M Bacon; Angela R Wateska; Maria Elena Bottazzi; Eric Dumonteil; Peter J Hotez
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

3.  Synthesis and Evaluation of Oxyguanidine Analogues of the Cysteine Protease Inhibitor WRR-483 against Cruzain.

Authors:  Brian D Jones; Anna Tochowicz; Yinyan Tang; Michael D Cameron; Laura-Isobel McCall; Ken Hirata; Jair L Siqueira-Neto; Sharon L Reed; James H McKerrow; William R Roush
Journal:  ACS Med Chem Lett       Date:  2015-12-15       Impact factor: 4.345

4.  Neuromuscular electrical stimulation in a patient with chronic heart failure due to chagas disease: a case report.

Authors:  Hugo Souza Bittencourt; Erenaldo de Souza Rodrigues Junior; Cristiano Gonçalves da Cruz; Alessandro Mezzani; Francisco José Farias Borges dos Reis; Vitor Oliveira Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

5.  The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America.

Authors:  Bruce Y Lee; Kristina M Bacon; Diana L Connor; Alyssa M Willig; Rachel R Bailey
Journal:  PLoS Negl Trop Dis       Date:  2010-12-14

6.  Economic evaluation of environmental health interventions to support decision making.

Authors:  Guy Hutton
Journal:  Environ Health Insights       Date:  2008-12-19

7.  New prescriptions for neglected diseases.

Authors:  James Maskalyk
Journal:  Open Med       Date:  2007-08-01

Review 8.  Nano-Medicines a Hope for Chagas Disease!

Authors:  Satabdi Datta Choudhury
Journal:  Front Mol Biosci       Date:  2021-06-01

9.  Combining residual insecticide spraying campaigns with targeted detection and specific chemotherapy for Trypanosoma cruzi infection in children.

Authors:  Ricardo E Gürtler
Journal:  PLoS Negl Trop Dis       Date:  2007-12-26

10.  Opportunity cost for early treatment of Chagas disease in Mexico.

Authors:  Janine M Ramsey; Miguel Elizondo-Cano; Gilberto Sanchez-González; Adriana Peña-Nieves; Alejandro Figueroa-Lara
Journal:  PLoS Negl Trop Dis       Date:  2014-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.